Platinum-Based Chemotherapy Drug Has Significantly Increased Survival Rates in Testicular Cancer

A new study testing the effectiveness of a platinum-based chemotherapy drug in treating testicular cancer reveals that the survival rate in British men suffering from the condition increased by 96 percent.

Figures compiled by Cancer Research UK show that 96 percent men have successfully been treated for testicular cancer, which is a big improvement since the 1970s when the survival rate was lower than 70 percent, the Independent reported.

Cisplatin had first been identified as a compound in the 19th century but researchers did not realise its application in oncology until the late 1970s.

Despite its side-effects, ranging from numbness in fingers and toes to tinnitus and hearing loss, the compound is one of the most commonly-used cancer drugs.

Source: ANI